BioGaia AB Series B | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
315,875.00
481,802.00
483,241.00
534,696.00
615,003.00
741,870
Cost of Goods Sold (COGS) incl. D&A
104,246.00
133,696.00
148,965.00
148,823.00
153,423.00
187,901
Gross Income
211,629.00
348,106.00
334,276.00
385,873.00
461,580.00
553,969
SG&A Expense
131,772.00
158,934.00
183,759.00
190,862.00
223,110.00
278,559
EBIT
79,857.00
189,172.00
150,517.00
195,011.00
238,470.00
275,410
Unusual Expense
-
-
-
-
842.00
7,004
Non Operating Income/Expense
1,178.00
971.00
6,570.00
803.00
4,009.00
4,960
Pretax Income
83,760.00
192,525.00
157,418.00
197,243.00
233,731.00
278,095
Income Tax
19,572.00
44,536.00
36,062.00
36,710.00
52,347.00
63,362
Equity in Affiliates
-
-
65.00
1,184.00
820.00
500
Consolidated Net Income
64,188.00
147,989.00
121,291.00
159,349.00
180,564.00
214,233
Net Income
61,722.00
147,406.00
121,408.00
159,633.00
180,564.00
214,890
Net Income After Extraordinaries
61,722.00
147,406.00
121,408.00
91,698.00
180,564.00
214,890
Net Income Available to Common
61,722.00
147,406.00
121,408.00
227,568.00
180,564.00
214,890
EPS (Basic)
3.57
8.53
7.01
13.13
10.42
12.40
Basic Shares Outstanding
17,271.00
17,271.00
17,309.00
17,336.00
17,336.50
17,336.50
EPS (Diluted)
3.56
8.53
7.01
13.13
10.42
12.40
Diluted Shares Outstanding
17,358.00
17,271.00
17,309.00
17,336.00
17,336.50
17,336.50
EBITDA
85,398.00
194,824.00
157,065.00
202,086.00
245,155.00
282,956
Non-Operating Interest Income
5,081.00
2,382.00
331.00
1,429.00
112.00
641
Minority Interest Expense
2,466.00
583.00
117.00
284.00
-
657

About BioGaia AB

View Profile
Address
Kungsbroplan 3
Stockholm AB 112 27
Sweden
Employees -
Website http://www.biogaia.com
Updated 07/08/2019
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment is comprised of sales of drops, oral rehydration solutions (ORS), digestive health tablets and also cultures as an ingredient in a licensee's products, as well as royalties pertaining to pediatric products.